Hoffmann-La Roche purchases MMP portfolio license
CUPERTINO, Calif. – March 26, 2009 – Alliacense today announced that Hoffmann-La Roche Ltd has purchased a Moore Microprocessor Patent™ (MMP) Portfolio license from The TPL Group. Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.
“We are pleased with Roche’s decision to purchase an MMP Portfolio license”, said Andre-Pascal Chauvin, VP of Licensing in Alliacense’s European office. “Recently comforted by the positive decision of the German Federal Patent Court in Munich our MMP Portfolio is more than ever adding real value to market success, and enabling real growth.”
